{"id":"irbesartan-aprovel","safety":{"commonSideEffects":[{"rate":"approximately 9%","effect":"Dizziness"},{"rate":"approximately 3%","effect":"Fatigue"},{"rate":"approximately 7%","effect":"Musculoskeletal pain"},{"rate":"approximately 1-2%","effect":"Hyperkalemia"},{"rate":"less than 2%","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1513","moleculeType":"Small molecule","molecularWeight":"428.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an angiotensin II receptor blocker (ARB), irbesartan selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. This prevents angiotensin II-mediated vasoconstriction and sodium retention, leading to vasodilation and reduced blood volume, thereby decreasing systemic blood pressure. It is commonly used in hypertension and diabetic nephropathy where it provides both blood pressure reduction and renal protective effects.","oneSentence":"Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:29.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Diabetic nephropathy in patients with type 2 diabetes and hypertension"}]},"trialDetails":[{"nctId":"NCT03476603","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Irbesartan","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT02842359","phase":"PHASE4","title":"Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-08-23","conditions":"Type 2 Diabetes Mellitus","enrollment":11},{"nctId":"NCT00657059","phase":"PHASE3","title":"Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2007-09","conditions":"IgA Nephropathy","enrollment":151},{"nctId":"NCT00389168","phase":"PHASE2, PHASE3","title":"Irbesartan and Atenolol in Hypertensive Heart Disease","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"1995-04","conditions":"Hypertension","enrollment":115},{"nctId":"NCT01992796","phase":"PHASE3","title":"Angiotensin II Antagonist in Severe Sepsis","status":"UNKNOWN","sponsor":"University of Salerno","startDate":"2014-01","conditions":"Severe Sepsis","enrollment":300},{"nctId":"NCT00791830","phase":"PHASE3","title":"Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2009-04","conditions":"Kidney Failure, Chronic","enrollment":82},{"nctId":"NCT00362037","phase":"PHASE4","title":"I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-03","conditions":"Hypertension","enrollment":281},{"nctId":"NCT00362258","phase":"PHASE4","title":"I PREVENT - Irbesartan In Hypertensive Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Hypertension","enrollment":797},{"nctId":"NCT00335673","phase":"PHASE4","title":"I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Hypertension","enrollment":1630},{"nctId":"NCT00742066","phase":"NA","title":"Role of AT1-receptor Blockers in Insulin-induced Vasodilation.","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2008-03","conditions":"Hypertension, Insulin Resistance, Microcirculation","enrollment":32},{"nctId":"NCT01238705","phase":"PHASE4","title":"Combined Antihypertensive Therapy and Sexual Dysfunction","status":"UNKNOWN","sponsor":"LanZhou University","startDate":"2008-04","conditions":"Hypertension, Sexual Dysfunction","enrollment":280},{"nctId":"NCT00249795","phase":"PHASE3","title":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Atrial Fibrillation, Cardiovascular Disease","enrollment":9016},{"nctId":"NCT00613496","phase":"PHASE4","title":"Irbesartan and Adhesion Molecules in AF","status":"UNKNOWN","sponsor":"University of Magdeburg","startDate":"2009-05","conditions":"Persistent Atrial Fibrillation","enrollment":60},{"nctId":"NCT00350038","phase":"PHASE4","title":"Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-02","conditions":"Hypertension, Dyslipidemia","enrollment":60},{"nctId":"NCT00264212","phase":"PHASE4","title":"AMISH : Aprovel for Management of Isolated Systolic Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Hypertension","enrollment":436},{"nctId":"NCT00564187","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-02","conditions":"Hypertension","enrollment":115},{"nctId":"NCT00561964","phase":"PHASE3","title":"Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-01","conditions":"Hypertension","enrollment":241}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD PHOSPHORUS INCREASED"},{"count":1,"reaction":"BLOOD URIC ACID INCREASED"},{"count":1,"reaction":"DIABETES MELLITUS INADEQUATE CONTROL"},{"count":1,"reaction":"HALO VISION"},{"count":1,"reaction":"PHOTOPSIA"},{"count":1,"reaction":"VISUAL IMPAIRMENT"}],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Irbesartan (Aprovel)","genericName":"Irbesartan (Aprovel)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes and hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}